{
  "type": "ref",
  "text": "CD82 expression was significantly reduced in lymph node metastases.\n",
  "self": {
    "NER": {
      "answers": [],
      "QG_hash=ThomasNLG/t5-qg_squad1-en": {
        "questions": []
      }
    },
    "NOUN": {
      "answers": [
        "CD82 expression",
        "lymph node metastases"
      ],
      "QG_hash=ThomasNLG/t5-qg_squad1-en": {
        "questions": [
          "What was significantly reduced in lymph node metastases?",
          "What type of cancers were the effects of CD82?"
        ]
      }
    }
  },
  "asked": {
    "What type of antibody was found in 58.9% of primary tumors?": {
      "QA_hash=ThomasNLG/t5-qa_squad2neg-en": {
        "answer": "unanswerable",
        "answerability": 0.00351560115814209,
        "ground_truth": {
          "Bcl-xL": {
            "bertscore": 0.6495962142944336,
            "f1": 0
          }
        }
      }
    },
    "What percentage of primary tumors were positive for Bcl-xL Bax and": {
      "QA_hash=ThomasNLG/t5-qa_squad2neg-en": {
        "answer": "unanswerable",
        "answerability": 0.00105208158493042,
        "ground_truth": {
          "44.6%": {
            "bertscore": 0.5949743390083313,
            "f1": 0
          },
          "28.6%": {
            "bertscore": 0.5954959988594055,
            "f1": 0
          },
          "58.9%": {
            "bertscore": 0.6192649602890015,
            "f1": 0
          },
          "63.6%": {
            "bertscore": 0.6080643534660339,
            "f1": 0
          }
        }
      }
    },
    "What percentage of lymph node metastases were positive for Bcl-xL Ba": {
      "QA_hash=ThomasNLG/t5-qa_squad2neg-en": {
        "answer": "unanswerable",
        "answerability": 0.0036933422088623047,
        "ground_truth": {
          "45.5%": {
            "bertscore": 0.6090081334114075,
            "f1": 0
          },
          "72.7%": {
            "bertscore": 0.6069919466972351,
            "f1": 0
          }
        }
      }
    },
    "What was the percentage of primary tumors that had Bcl-xL Bax and": {
      "QA_hash=ThomasNLG/t5-qa_squad2neg-en": {
        "answer": "unanswerable",
        "answerability": 0.0013912320137023926,
        "ground_truth": {
          "We": {
            "bertscore": 0.6054112315177917,
            "f1": 0
          }
        }
      }
    },
    "What immunostaining was found in 58.9% of primary tumors?": {
      "QA_hash=ThomasNLG/t5-qa_squad2neg-en": {
        "answer": "unanswerable",
        "answerability": 0.0006522536277770996,
        "ground_truth": {
          "positive Bcl-xL Bax": {
            "bertscore": 0.6466283202171326,
            "f1": 0
          },
          "p53": {
            "bertscore": 0.6259340643882751,
            "f1": 0
          }
        }
      }
    },
    "What percentage of lymph nodes were positive for Bcl-xL Bax and": {
      "QA_hash=ThomasNLG/t5-qa_squad2neg-en": {
        "answer": "unanswerable",
        "answerability": 0.0018729567527770996,
        "ground_truth": {
          "the studied primary tumors": {
            "bertscore": 0.6620428562164307,
            "f1": 0
          }
        }
      }
    }
  }
}